RSV Immunization: Real-World data Reveals Varied Uptake and Calls for Enhanced Strategies

New data highlights significant disparities in the uptake of Respiratory Syncytial Virus (RSV) immunizations across different countries and demographic groups, prompting calls for more robust public health initiatives.

Global Uptake of Nirsevimab in Infants Shows Mixed Results

Real-world data from the 2023-2024 season indicates ⁤a 51.2% uptake of nirsevimab among eligible infants in the united States. Uptake was notably‍ higher in specific subgroups, including preterm infants, those with at least one comorbidity, and infants from Hispanic backgrounds.

Internationally,coverage rates⁣ varied considerably. France⁤ reported a 76.5% coverage rate, with infants younger than 3 months showing ‍higher‍ uptake than those aged 3-12 months. Luxembourg lead with 83.8% coverage,‍ followed⁢ by italy at 68.7%, ⁤and a combined Catalonia-Andorra⁣ region at 60.2%.

Though, subgroup analyses revealed a concerning trend: children who had ⁣previously experienced ⁤RSV or other acute ⁢respiratory infections where less likely to receive nirsevimab. This suggests a ‍potential gap in reaching infants moast vulnerable to severe RSV disease.

Maternal Vaccination Coverage Remains Low

Maternal RSV vaccine coverage during pregnancy stood at 30.5% (95% CI, 20.6-42.6). ⁣The data revealed significant disparities in uptake based on insurance‍ status, with women lacking health insurance or having statutory coverage showing lower ⁤rates compared to those with private insurance. Furthermore, black and Hispanic women⁣ had lower vaccination rates than their non-Hispanic White counterparts.

Older Adult Vaccination Rates Lag ⁣Behind

Population-based studies assessing RSV vaccine uptake in adults aged 60 years and older demonstrated an average rate of 18.2% (95% CI, 10.8-28.9) during the 2023-2024‍ period. Similar to infant and maternal vaccination trends,uptake was higher among adults over 75 years,those with comorbidities,and immunocompromised individuals.However,‍ Black and Hispanic populations also exhibited⁣ lower ⁤vaccination rates in this age group.

Researchers expressed concern over the “concerningly ⁣low uptake” among pregnant women and older adults, notably given the availability ⁤of effective prevention tools. They emphasized the need for coordinated national,clinical,and public health efforts to improve immunization rates in these high-risk populations.

World health Organization Urges Global Action ⁤on RSV Prevention

in a significant move to address the global burden of RSV, the World Health Organization (WHO) published its first position paper on RSV immunization in infants and ⁣young children in May. The paper underscores the urgent need for global action,highlighting that RSV is the leading cause of pediatric morbidity and mortality.

In 2019,an estimated 100,000 children younger than ⁣5 years died from RSV-related lower respiratory tract infections,accounting for approximately 2% of all deaths in this age group. Critically, about half of these deaths⁣ occurred in infants younger‍ than 5 months, with 97% ⁣of all pediatric RSV deaths occurring in low- and middle-income countries. Globally, RSV contributes to an estimated 3.6 million hospitalizations annually in children under five.

The WHO recommends that all countries implement immunization⁣ programs⁤ to prevent severe RSV disease in ⁤vulnerable groups. The choice between maternal vaccination and the use of long-acting monoclonal antibodies, such as nirsevimab, should ⁢be guided by local factors, ‍including health system integration, cost-effectiveness, and overall feasibility.

Germany’s Robert⁤ Koch Institute also provides supplementary⁢ guidance on RSV immunization,offering detailed details⁣ on nirsevimab and adult vaccinations through its‍ fact sheets.